MeiraGTx Holdings PLC (MGTX)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$5.63

Buy

$5.65

arrow-up$0.22 (+4.06%)

MeiraGTx Holdings PLC is a clinical stage gene therapy company. Its pipeline products include AAV-CNGB3, AAV-CNGA3. AAV-UPF1, West AMD, Dry AMD, and others. Geographically, the company generates a majority of its revenue from the United Kingdom.
Prices updated at 12 May 2025, 18:55 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up4.23%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Keith R. Harris, PhD
CEO
Dr. Alexandria Forbes, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
381
Head office
450 East 29th Street
New York
United States
10016
mobile
+1 646 860-7985
letter
-
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Dr. Thomas E. Shenk, PhD
Independent Director
0.09m--0.31m-
Ms. Nicole Seligman
Independent Director
0.10m--0.32m-
Dr. Stuart Naylor, PhD
Chief Development Officer
0.50m0.60m-2.03m-
Dr. Alexandria Forbes, PhD
President, Chief Executive Officer and Director
0.84m2.20m-6.88m-
Dr. Robert K. Zeldin, M.D.
Chief Medical Officer
-----
Mr. Richard Giroux
Chief Accounting Officer, Chief Operating Officer and Chief Financial Officer
0.71m2.14m-6.69m-
Dr. Keith R. Harris, PhD
Chairman of the Board
0.16m--0.53m-
Dr. Ellen Hukkelhoven, PhD
Director
---0.22m-
Lord Neil Mendoza
Independent Director
0.10m--0.31m-
Mr. Robert J. Wollin
General Counsel and Secretary
-----
Dr. Debra Yu, M.D.
Independent Director
0.08m--0.30m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
Perceptive Advisors LLC12,581,1032.11051--30 Apr 202515.74
Sanofi SA12,197,737-7500000159.65133930 Apr 202515.61
Sanofi12,197,73749.83625--30 Apr 202515.26
Johnson & Johnson6,641,06410.4743--30 Apr 20258.31
Adage Capital Management LP5,229,099-5229099-30 Apr 20256.69

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
06 Jun 2024-Dr. Thomas E. Shenk, PhD--45,000--
06 Jun 2024-Ms. Nicole Seligman--45,000--
06 Jun 2024-Dr. Ellen Hukkelhoven, PhD--45,000--
06 Jun 2024-Lord Neil Mendoza--45,000--
06 Jun 2024-Dr. Debra Yu, M.D.--45,000--
06 Jun 2024-Dr. Keith R. Harris, PhD--75,000--
05 Jun 2024-Dr. Keith R. Harris, PhD-----
05 Jun 2024-Dr. Keith R. Harris, PhD--50,000--
05 Jun 2024-Ambassador Martin Indyk, PhD-----
06 Jun 2024-Ambassador Martin Indyk, PhD--45,000--
05 Jun 2024-Ambassador Martin Indyk, PhD--35,000--
28 May 2024-Mr. Richard Giroux--837,426--
05 Apr 2024-Dr. Alexandria Forbes, PhD--1,372,504--
12 Mar 2024-Dr. Alexandria Forbes, PhD--1,373,504--
29 Feb 2024-Mr. Richard Giroux--840,426--
14 Jan 2024-Dr. Stuart Naylor, PhD--575,492--
17 Jan 2024-Dr. Stuart Naylor, PhD--150,000--
14 Jan 2024-Dr. Stuart Naylor, PhD--23,750--
14 Jan 2024-Dr. Stuart Naylor, PhD6.3670,997564,329--
14 Jan 2024-Dr. Alexandria Forbes, PhD--1,391,367--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.